Integrated Investment Consultants buys $586,683 stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Integrated Investment Consultants scooped up 2,937 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 14, 2016. The investment management firm now holds a total of 14,383 shares of Abbott Laboratories which is valued at $586,683.Abbott Laboratories makes up approximately 0.30% of Integrated Investment Consultants’s portfolio.

Other Hedge Funds, Including , Naples Global Advisors boosted its stake in ABT in the latest quarter, The investment management firm added 6 additional shares and now holds a total of 12,374 shares of Abbott Laboratories which is valued at $538,269. Abbott Laboratories makes up approx 0.21% of Naples Global Advisors’s portfolio.Cobiz Investment Management reduced its stake in ABT by selling 957 shares or 3.63% in the most recent quarter. The Hedge Fund company now holds 25,415 shares of ABT which is valued at $1,105,553. Abbott Laboratories makes up approx 0.27% of Cobiz Investment Management’s portfolio.Mcqueen Ball Associates reduced its stake in ABT by selling 419 shares or 0.9% in the most recent quarter. The Hedge Fund company now holds 46,321 shares of ABT which is valued at $1,979,760. Abbott Laboratories makes up approx 1.36% of Mcqueen Ball Associates’s portfolio.

Abbott Laboratories closed down -0.19 points or -0.46% at $40.79 with 88,18,965 shares getting traded on Friday. Post opening the session at $41.17, the shares hit an intraday low of $40.77 and an intraday high of $41.53 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Leave a Reply

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.